{"id":"W4410463909","doi":"10.1016/j.esmoop.2025.104766","title":"212P Cost-effectiveness analysis of ribociclib plus endocrine therapy (ET) versus ET alone in the adjuvant treatment of stage II and III pre and postmenopausal women with HR+/HER2− early breast cancer (EBC): A Canadian payer perspective","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Novartis (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; Ipsen; Eisai; Pfizer; Ministero della Salute; Incyte; Teva Pharmaceutical Industries; Gilead Sciences; Amgen; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine; Gynecology; Postmenopausal women; Adjuvant; Breast cancer; Cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002389819,0.0009742884,0.001227595,0.001401131,0.0004334521,0.001993057,0.001197236,0.001121457,0.007732614],"category_scores_gemma":[0.008589391,0.0004239644,0.004128912,0.002321193,0.0005051259,0.000515027,0.0005948725,0.001784956,0.000272516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03230618,"about_ca_system_score_gemma":0.04007467,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7579113,"about_ca_topic_score_gemma":0.7850356,"domain_scores_codex":[0.9978276,0.0008446988,0.0001007748,0.0001224256,0.0006444077,0.0004602033],"domain_scores_gemma":[0.9979389,0.000771787,0.0002877902,0.00004447185,0.0005671323,0.00038991],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.09884709,0.001943768,0.1006997,0.01393013,0.03882094,0.0009772726,0.0003347369,0.2273588,0.004178392,0.03512445,0.1034796,0.3743052],"study_design_scores_gemma":[0.03868882,0.01495755,0.521697,0.009333877,0.07268742,0.00186105,0.001417067,0.192392,0.002796755,0.01672928,0.1267439,0.0006952212],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5728347,0.1375759,0.005944058,0.03247945,0.001429902,0.004297948,0.1083483,0.0002683745,0.1368214],"genre_scores_gemma":[0.966161,0.01367154,0.002841304,0.002174603,0.000246692,0.0003116661,0.01018617,0.00003006449,0.004376949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2420887,"threshold_uncertainty_score":0.4870287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02366314475686798,"score_gpt":0.3695961573708598,"score_spread":0.3459330126139918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}